✉news HealthMedicine first seen 1 d ago, last 1 d ago, peak #37
Keros Therapeutics Enrolls First Patient in Phase 2 Rinvatercept DMD Trial
Keros Therapeutics has dosed the first patient in a Phase 2 clinical trial of rinvatercept, an investigational therapy for Duchenne muscular dystrophy. The milestone marks the start of patient enrollment in the study, a key step in testing whether the drug can benefit people with the progressive muscle-wasting disease. Details on trial sites and timelines have not been widely reported yet.
Why now: The start of patient dosing is a notable pipeline milestone for a potential new DMD treatment.
Keros TherapeuticsrinvaterceptDuchenne muscular dystrophy
Evidence
- Keros Therapeutics Enrolls First Patient in Phase 2 Rinvatercept DMD Trial · clinicaltrialvanguard.com
API: https://socialmediatrends-api.osmike.com/v1/trends/351090